new studyxīn yánjiū新研究to find / to discoverfāxiàn发现cholesterol-loweringjiàng dǎngùchún降胆固醇drug / medicationyàowù药物can reduce / can causekě shǐ可使diabetestángniàobìng糖尿病patientshuànzhě患者heart diseasexīnzàngbìng心脏病riskfēngxiǎn风险to reducejiàngdī降低30 percent / three-tenthssān chéng三成。
new study
xīn yánjiū
新研究
to find / to discover
fāxiàn
发现
cholesterol-lowering
jiàng dǎngùchún
降胆固醇
drug / medication
yàowù
药物
can reduce / can cause
kě shǐ
可使
diabetes
tángniàobìng
糖尿病
patients
huànzhě
患者
heart disease
xīnzàngbìng
心脏病
risk
fēngxiǎn
风险
to reduce
jiàngdī
降低
30 percent / three-tenths
sān chéng
三成
March 30, 2026
2026 nián 3 yuè 30 rì
2026年3月30日
to publish
fābiǎo
发表
structural particle
de
的
one (measure word for studies)
yī xiàng
一项
study
yánjiū
研究
to find / to discover
fāxiàn
发现
cholesterol-lowering
jiàng dǎngùchún
降胆固醇
drug / medication
yàowù
药物
evolocumab (cholesterol drug)
yīluòyóudānkàng
依洛尤单抗
can reduce
kě jiāng
可将
diabetes
tángniàobìng
糖尿病
patients
huànzhě
患者
for the first time
shǒucì
首次
major / serious
zhòngdà
重大
cardiovascular
xīn xuèguǎn
心血管
event / incident
shìjiàn
事件
risk
fēngxiǎn
风险
to reduce
jiàngdī
降低
31 percent
31%
31%